Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Rating) – Equities researchers at HC Wainwright boosted their FY2026 EPS estimates for shares of Mirum Pharmaceuticals in a report issued on Monday, November 14th. HC Wainwright analyst E. Arce now expects that the company will earn $8.42 per share for the year, up from their prior estimate of $8.25. HC Wainwright has a “Buy” rating and a $69.00 price objective on the stock. The consensus estimate for Mirum Pharmaceuticals’ current full-year earnings is ($4.12) per share.
Other analysts also recently issued research reports about the company. Raymond James boosted their price target on Mirum Pharmaceuticals from $75.00 to $88.00 and gave the company a “strong-buy” rating in a research note on Tuesday, October 25th. Citigroup cut their price target on shares of Mirum Pharmaceuticals from $38.00 to $34.00 and set a “buy” rating on the stock in a report on Thursday, November 10th.
Mirum Pharmaceuticals Price Performance
Institutional Inflows and Outflows
A number of large investors have recently bought and sold shares of MIRM. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of Mirum Pharmaceuticals during the 1st quarter valued at approximately $41,000. Lazard Asset Management LLC acquired a new stake in Mirum Pharmaceuticals during the second quarter valued at $47,000. Legal & General Group Plc increased its holdings in Mirum Pharmaceuticals by 2,193.7% in the second quarter. Legal & General Group Plc now owns 6,583 shares of the company’s stock valued at $128,000 after buying an additional 6,296 shares in the last quarter. American International Group Inc. raised its position in shares of Mirum Pharmaceuticals by 315.7% in the second quarter. American International Group Inc. now owns 7,436 shares of the company’s stock worth $145,000 after acquiring an additional 5,647 shares during the period. Finally, International Biotechnology Trust PLC purchased a new stake in shares of Mirum Pharmaceuticals during the 3rd quarter worth about $193,000. 89.62% of the stock is owned by institutional investors and hedge funds.
Insiders Place Their Bets
In other news, Director Niall O’donnell sold 32,109 shares of the business’s stock in a transaction dated Monday, November 14th. The stock was sold at an average price of $19.60, for a total value of $629,336.40. Following the completion of the transaction, the director now owns 1,714,888 shares of the company’s stock, valued at approximately $33,611,804.80. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 33.27% of the stock is owned by insiders.
Mirum Pharmaceuticals Company Profile
Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease.
- Get a free copy of the StockNews.com research report on Mirum Pharmaceuticals (MIRM)
- Power Integrations Stock Can Power Your Portfolio
- Don’t Chase Walmart Higher, Wait For Extra Low Prices
- Home Depot Results (and Institutions) Are A Catalyst For Lowe’s?
- Agilent Remains In Buy Range Ahead Of Next Week’s Q4 Report
- Three Penny Stocks Making Big Moves In November
Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.